Show simple item record

dc.contributor.authorDrilling, Amanda J
dc.contributor.authorOoi, Mian L
dc.contributor.authorMiljkovic, Dijana
dc.contributor.authorJames, Craig
dc.contributor.authorSpeck, Peter Gerald
dc.contributor.authorVreugde, Sarah
dc.contributor.authorClark, Jason
dc.contributor.authorWormald, Peter John
dc.date.accessioned2017-04-06T06:07:11Z
dc.date.available2017-04-06T06:07:11Z
dc.date.issued2017-02-24
dc.identifier.citationDrilling AJ, Ooi ML, Miljkovic D, James C, Speck P, Vreugde S, Clark J and Wormald P-J (2017) Long-Term Safety of Topical Bacteriophage Application to the Frontal Sinus Region. Front. Cell. Infect. Microbiol. 7:49. doi: 10.3389/fcimb.2017.00049en
dc.identifier.issn2235-2988
dc.identifier.urihttp://hdl.handle.net/2328/37112
dc.descriptionCopyright © 2017 Drilling, Ooi, Miljkovic, James, Speck, Vreugde, Clark and Wormald. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en
dc.description.abstractBackground: Staphylococcus aureus biofilms contribute negatively to a number of chronic conditions, including chronic rhinosinusitis (CRS). With the inherent tolerance of biofilm-bound bacteria to antibiotics and the global problem of bacterial antibiotic resistance, the need to develop novel therapeutics is paramount. Phage therapy has previously shown promise in treating sinonasal S. aureus biofilms. Methods: This study investigates the long term (20 days) safety of topical sinonasal flushes with bacteriophage suspensions. The bacteriophage cocktail NOV012 against S. aureus selected for this work contains two highly characterized and different phages, P68 and K710. Host range was assessed against S. aureus strains isolated from CRS patients using agar spot tests. NOV012 was applied topically to the frontal sinus region of sheep, twice daily for 20 days. General sheep wellbeing, mucosal structural changes and inflammatory load were assessed to determine safety of NOV012 application. Results: NOV012 could lyse 52/61 (85%) of a panel of locally derived CRS clinical isolates. Application of NOV012 to the frontal sinuses of sheep for 20 days was found to be safe, with no observed inflammatory infiltration or tissue damage within the sinus mucosa. Conclusion: NOV012 cocktail appears safe to apply for extended periods to sheep sinuses and it could infect and lyse a wide range of S. aureus CRS clinical isolates. This indicates that phage therapy has strong potential as a treatment for chronic bacterial rhinosinusitis.en
dc.language.isoen
dc.publisherFrontiers Media S.A.en
dc.rightsCopyright © 2017 Drilling, Ooi, Miljkovic, James, Speck, Vreugde, Clark and Wormald.en
dc.subjectbacteriophage,en
dc.subjecttherapeutic safety,en
dc.subjecttopical,en
dc.subjectinflammation,en
dc.subjectcilia,en
dc.subjectStaphylococcus aureusen
dc.titleLong-Term Safety of Topical Bacteriophage Application to the Frontal Sinus Regionen
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.3389/fcimb.2017.00049en
dc.rights.holderDrilling, Ooi, Miljkovic, James, Speck, Vreugde, Clark and Wormald.en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record